GlassScriptPhysician profile
Louis Duchin
NPI 1457309023
$1,254.18
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.99 · 2020: $149 · 2021: $521 · 2022: $505.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $755.33 | 2020-2022 | |
| Eisai INC. | $115.12 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $56.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.02 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $50.58 | 2019-2021 | |
| Lundbeck LLC | $48.01 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $43.90 | 2021 | |
| Indivior INC. | $27.13 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $24.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.03 | 2022 | |
| Bausch Health US, LLC | $17.97 | 2022 | |
| Axsome Therapeutics, INC. | $14.49 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.23 | 2020 | |
| Biodelivery Sciences International, INC. | $11.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Duchin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.